ERBB2 and breast carcinoma: These 44 shared miRNAs were significantly associated with critical aspects of breast cancer progression, such as receptor-negative subtypes, including progesterone receptor-negative, estrogen receptor-negative, and HER2-negative breast cancers, as well as ductal carcinoma and invasive breast carcinoma.